Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.

Kalil RS, Carpenter MA, Ivanova A, Gravens-Mueller L, John AA, Weir MR, Pesavento T, Bostom AG, Pfeffer MA, Hunsicker LG.

Am J Kidney Dis. 2017 Aug 9. pii: S0272-6386(17)30801-6. doi: 10.1053/j.ajkd.2017.06.013. [Epub ahead of print]

PMID:
28801121
2.

Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.

Merhi B, Shireman T, Carpenter MA, Kusek JW, Jacques P, Pfeffer M, Rao M, Foster MC, Kim SJ, Pesavento TE, Smith SR, Kew CE, House AA, Gohh R, Weiner DE, Levey AS, Ix JH, Bostom A.

Am J Kidney Dis. 2017 Sep;70(3):377-385. doi: 10.1053/j.ajkd.2017.04.014. Epub 2017 Jun 2.

PMID:
28579423
3.

Urinary Markers of Fibrosis and Risk of Cardiovascular Events and Death in Kidney Transplant Recipients: The FAVORIT Trial.

Park M, Katz R, Shlipak MG, Weiner D, Tracy R, Jotwani V, Hughes-Austin J, Gabbai F, Hsu CY, Pfeffer M, Bansal N, Bostom A, Gutierrez O, Sarnak M, Levey A, Ix JH.

Am J Transplant. 2017 Oct;17(10):2640-2649. doi: 10.1111/ajt.14284. Epub 2017 Apr 26.

PMID:
28371433
4.

Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.

Foster MC, Weiner DE, Bostom AG, Carpenter MA, Inker LA, Jarolim P, Joseph AA, Kusek JW, Pesavento T, Pfeffer MA, Rao M, Solomon SD, Levey AS.

Am J Transplant. 2017 Sep;17(9):2390-2399. doi: 10.1111/ajt.14258. Epub 2017 Mar 30.

PMID:
28257169
5.

More than skin deep? Potential nicotinamide treatment applications in chronic kidney transplant recipients.

Bostom AG, Merhi B, Walker J, Robinson-Bostom L.

World J Transplant. 2016 Dec 24;6(4):658-664. doi: 10.5500/wjt.v6.i4.658. Review.

6.

Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial.

Ix JH, Katz R, Bansal N, Foster M, Weiner DE, Tracy R, Jotwani V, Hughes-Austin J, McKay D, Gabbai F, Hsu CY, Bostom A, Levey AS, Shlipak MG.

Am J Kidney Dis. 2017 Mar;69(3):410-419. doi: 10.1053/j.ajkd.2016.10.019. Epub 2016 Dec 23.

PMID:
28024930
7.

Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

Dad T, Tighiouart H, Joseph A, Bostom A, Carpenter M, Hunsicker L, Kusek JW, Pfeffer M, Levey AS, Weiner DE.

Am J Kidney Dis. 2016 Aug;68(2):277-286. doi: 10.1053/j.ajkd.2016.01.019. Epub 2016 Mar 2.

8.

B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients.

Jarolim P, Claggett BL, Conrad MJ, Carpenter MA, Ivanova A, Bostom AG, Kusek JW, Hunsicker LG, Jacques PF, Gravens-Mueller L, Finn P, Solomon SD, Weiner DE, Levey AS, Pfeffer MA.

Transplantation. 2017 Jan;101(1):182-190. doi: 10.1097/TP.0000000000001080.

PMID:
26910333
9.

Adiposity patterns and the risk for ESRD in postmenopausal women.

Franceschini N, Gouskova NA, Reiner AP, Bostom A, Howard BV, Pettinger M, Umans JG, Brookhart MA, Winkelmayer WC, Eaton CB, Heiss G, Fine JP.

Clin J Am Soc Nephrol. 2015 Feb 6;10(2):241-50. doi: 10.2215/CJN.02860314. Epub 2014 Dec 1.

10.

Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial.

Weir MR, Gravens-Muller L, Costa N, Ivanova A, Manitpisitkul W, Bostom AG, Diamantidis CJ; FAVORIT Study Investigators.

Transplantation. 2015 May;99(5):1003-8. doi: 10.1097/TP.0000000000000454.

11.

Effect of niacin on FGF23 concentration in chronic kidney disease.

Rao M, Steffes M, Bostom A, Ix JH.

Am J Nephrol. 2014;39(6):484-90. doi: 10.1159/000362424. Epub 2014 May 20.

12.

BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Carpenter MA, John A, Weir MR, Smith SR, Hunsicker L, Kasiske BL, Kusek JW, Bostom A, Ivanova A, Levey AS, Solomon S, Pesavento T, Weiner DE.

J Am Soc Nephrol. 2014 Jul;25(7):1554-62. doi: 10.1681/ASN.2013040435. Epub 2014 Mar 13.

13.

Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study.

Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW.

Clin Transplant. 2012 Jul-Aug;26(4):E438-46. doi: 10.1111/j.1399-0012.2012.01676.x. Epub 2012 Jul 9.

14.

Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.

Weiner DE, Carpenter MA, Levey AS, Ivanova A, Cole EH, Hunsicker L, Kasiske BL, Kim SJ, Kusek JW, Bostom AG.

Am J Transplant. 2012 Sep;12(9):2437-45. doi: 10.1111/j.1600-6143.2012.04101.x. Epub 2012 May 17.

15.

Cognitive dysfunction and depression in adult kidney transplant recipients: baseline findings from the FAVORIT Ancillary Cognitive Trial (FACT).

Troen AM, Scott TM, D'Anci KE, Moorthy D, Dobson B, Rogers G, Weiner DE, Levey AS, Dallal GE, Jacques PF, Selhub J, Rosenberg IH; FACT Study Investigators.

J Ren Nutr. 2012 Mar;22(2):268-76.e1-3. doi: 10.1053/j.jrn.2011.07.009. Epub 2011 Dec 6.

16.

Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.

Bostom AG, Maclean AA, Maccubbin D, Tipping D, Giezek H, Hanlon WA.

J Clin Lipidol. 2011 Jul-Aug;5(4):281-7. doi: 10.1016/j.jacl.2011.03.455. Epub 2011 May 13.

PMID:
21784373
17.

Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.

Ix JH, Ganjoo P, Tipping D, Tershakovec AM, Bostom AG.

Am J Kidney Dis. 2011 Jun;57(6):963-5. doi: 10.1053/j.ajkd.2011.03.010. Epub 2011 Apr 15. No abstract available. Erratum in: Am J Kidney Dis. 2011 Oct;58(4):688. Dosage error in article text.

PMID:
21496982
18.

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M.

Circulation. 2011 Apr 26;123(16):1763-70. doi: 10.1161/CIRCULATIONAHA.110.000588. Epub 2011 Apr 11.

19.

Comparison of plasma clearance of iodixanol during versus after angiography.

Hu S, Akhlaghi F, Chitnis S, Chiu R, Go S, Rout P, Steffes M, Abbott JD, Dworkin L, Bostom A.

Am J Kidney Dis. 2010 Dec;56(6):1219-20. doi: 10.1053/j.ajkd.2010.08.020. No abstract available.

PMID:
21094917
20.

Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia.

Hu S, Shearer GC, Steffes MW, Harris WS, Bostom AG.

Am J Kidney Dis. 2011 Jan;57(1):181-2. doi: 10.1053/j.ajkd.2010.06.029. Epub 2010 Oct 8. No abstract available.

PMID:
20888102

Supplemental Content

Loading ...
Support Center